Effects of W100E-Leptin in streptozotocin-induced diabetic mice.

• Vique-Sánchez, José L. ^[1] ; López-Palacios, Tania P ^[2] ; Miranda-Ozuna, Jesús F. T. ^[2] ; Benítez-Cardoza, Claudia G. ^[2]
  1. [1] Universidad Autónoma de Baja California

     Universidad Autónoma de Baja California

     México

     
  2. [2] Laboratorio de Investigación Bioquímica, ENMyH-Instituto Politécnico Nacional, Ciudad de México, México
• Localización: Nutrición clínica y dietética hospitalaria, ISSN 0211-6057, Vol. 40, Nº. 3, 2020, págs. 153-161
• Idioma: inglés
• DOI: 10.12873/403vique
• Enlaces
  • Texto completo
• Resumen

  • Objectives: To determine the effects of W100E-Leptin in a streptozotocin-induced diabetic mice model (effects in the body weight, fasting serum glucose and glucose tolerance).

    Methods: Intraperitoneal W100E-Leptin application at 1 mg/kg for 13 days. We used 3 experimental groups (n=6). Group 1: Diabetes + W100E-Leptin (intraperitoneal administration), Group 2: Diabetes + buffer (vehicle) and Group 3: Healthy control + buffer (vehicle).

    Results: We determined the effects of W100E on the behavior of the mice, more active, more hair and a tendency to gain body weight. We did not observe any hypoglycemic effect of W100E-Leptin on serum glucose levels in the tests we performed.

    Conclusions: These results show us the need to characterize the effects of this hormone in diabetes. We will continue with the characterization of the change that is generated in the protein regulation caused by W100E-Leptin in the diabetes, to propose this hormone as an adjunct against diabetes.